Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants

NCT01487512 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Treatment A: Hydromorphone 8 mg
DRUG: Treatment B: Hydromorphone 16 mg
DRUG: Treatment C: Hydromorphone 32 mg
DRUG: Treatment D: Hydromorphone 64 mg

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.